[go: up one dir, main page]

CN115716833A - Preparation method of antiviral nucleoside analogue - Google Patents

Preparation method of antiviral nucleoside analogue Download PDF

Info

Publication number
CN115716833A
CN115716833A CN202110988001.1A CN202110988001A CN115716833A CN 115716833 A CN115716833 A CN 115716833A CN 202110988001 A CN202110988001 A CN 202110988001A CN 115716833 A CN115716833 A CN 115716833A
Authority
CN
China
Prior art keywords
formula
compound
reagent
acid
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110988001.1A
Other languages
Chinese (zh)
Inventor
田广辉
李建
谢元超
徐万斌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Wuhan Institute of Virology of CAS
Vigonvita Life Sciences Co Ltd
Original Assignee
Shanghai Institute of Materia Medica of CAS
Wuhan Institute of Virology of CAS
Suzhou Vigonvita Life Sciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS, Wuhan Institute of Virology of CAS, Suzhou Vigonvita Life Sciences Co Ltd filed Critical Shanghai Institute of Materia Medica of CAS
Priority to CN202110988001.1A priority Critical patent/CN115716833A/en
Publication of CN115716833A publication Critical patent/CN115716833A/en
Pending legal-status Critical Current

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention belongs to the field of medicines, and particularly relates to a preparation method of an antiviral nucleoside analogue, which comprises the following steps: reacting the compound shown in the formula (VIII) with a reagent A to generate a compound shown in the formula (VII); reacting the compound shown in the formula (VII) with a reagent B under the action of a metal reagent M to generate a compound shown in a formula (VI); reacting the compound shown in the formula (VI) with a reagent C to generate a compound shown in the formula (V); reacting the compound shown in the formula (V) with a reagent D to generate a compound shown in the formula (IV); reacting the compound shown in the formula (IV) with a reagent E to generate a compound shown in a formula (III); reacting the compound shown in the formula (III) with a reagent F to generate a compound shown in the formula (II); reacting the compound of formula (II) with a reagent G to produce the compound of formula (I). The reaction condition is mild, the process is easy to control, the operation is simple, and the method is suitable for industrial large-scale production.

Description

一种抗病毒核苷类似物的制备方法A kind of preparation method of antiviral nucleoside analog

技术领域technical field

本发明涉及医药领域,具体涉及一种抗病毒核苷类似物的制备方法。The invention relates to the field of medicine, in particular to a preparation method of an antiviral nucleoside analogue.

背景技术Background technique

新型冠状病毒肺炎(COVID-19)是由2019新型冠状病毒(SARS-CoV-2)感染引起的一种急性呼 吸道传染病。疫苗是预防病毒感染最有效的办法,目前世界各国已陆续开始接种SARS-CoV-2疫苗。 因此,开发出低毒高效的抗病毒药物,对COVID-19的防治将具有重要的意义。Novel coronavirus pneumonia (COVID-19) is an acute respiratory infectious disease caused by 2019 novel coronavirus (SARS-CoV-2) infection. Vaccines are the most effective way to prevent viral infections, and countries around the world have gradually begun to vaccinate against SARS-CoV-2. Therefore, the development of antiviral drugs with low toxicity and high efficiency will be of great significance to the prevention and treatment of COVID-19.

SARS-CoV-2是一种正链RNA病毒,它的复制是由病毒非结构蛋白(nsp)的多亚基复制/转录复 合物介导的,这种复合物的核心成分是RNA依赖的RNA聚合酶(RdRp,也被称为nsp12)。RNA依赖 的RNA聚合酶的活性中心具有高保守性,是开发抗SARS-CoV-2药物的重要靶点,已经获批的和在研 的核苷类似物药物可能具有抗SARS-CoV-2感染的潜力。SARS-CoV-2 is a positive-strand RNA virus whose replication is mediated by a multi-subunit replication/transcription complex of the viral nonstructural protein (nsp), a core component of which is the RNA-dependent RNA Polymerase (RdRp, also known as nsp12). The active center of RNA-dependent RNA polymerase is highly conserved and is an important target for the development of anti-SARS-CoV-2 drugs. Nucleoside analogue drugs that have been approved and under research may have anti-SARS-CoV-2 infection potential.

VV116是一个可口服的核苷类抗SARS-CoV-2候选药物:VV116 is an orally available nucleoside anti-SARS-CoV-2 drug candidate:

Figure BDA0003231447290000011
Figure BDA0003231447290000011

其进入体内后在酶的作用下经过水解和逐级磷酸化转变为核苷三磷酸活性形式,该三磷酸能够插 入到病毒正在延长的RNA链中,终止其延长以抑制病毒增殖。VV116在VeroE6细胞上具有较强的抗 SARS-CoV-2活性和较低的细胞毒性,优于对照药瑞德西韦;在表达新冠病毒受体人源ACE2的腺病毒 转导小鼠模型上,可通过一天一次口服给药,可剂量依赖性地降低小鼠肺部的病毒载量。而且,该候 选药物对其它病毒(如呼吸道合胞病毒、登革热病毒、丙肝病毒、寨卡病毒等)也有抑制活性,具有 广谱抗病毒特点。After entering the body, it undergoes hydrolysis and gradual phosphorylation under the action of enzymes and converts it into an active form of nucleoside triphosphates. The triphosphates can be inserted into the RNA chain of the virus being extended to terminate its extension to inhibit virus proliferation. VV116 has strong anti-SARS-CoV-2 activity and low cytotoxicity on VeroE6 cells, which is superior to the control drug remdesivir; on an adenovirus-transduced mouse model expressing the new coronavirus receptor human ACE2 , which can be administered orally once a day, can dose-dependently reduce the viral load in the lungs of mice. Moreover, the candidate drug also has inhibitory activity against other viruses (such as respiratory syncytial virus, dengue virus, hepatitis C virus, Zika virus, etc.), and has broad-spectrum antiviral characteristics.

VV116是一种极具开发前景的COVID-19治疗药物,因此,寻找一种高效、经济、实用的制备方 法,将有助于该候选药物的进一步开发,对预防和/或治疗COVID-19具有重要意义。VV116 is a highly promising COVID-19 therapeutic drug, therefore, finding an efficient, economical and practical preparation method will contribute to the further development of this candidate drug, which has the potential to prevent and/or treat COVID-19. Significance.

发明内容Contents of the invention

发明要解决的问题The problem to be solved by the invention

本发明提供一种抗病毒核苷类似物VV116的制备方法,该方法反应条件温和,过程易控,操作简 单,适合工业化大规模生产。The invention provides a preparation method of antiviral nucleoside analog VV116, the method has mild reaction conditions, easy process control, simple operation and is suitable for large-scale industrial production.

用于解决问题的方案solutions to problems

本发明提供一种式(Ⅰ)化合物的制备方法,其包括以下步骤:The present invention provides a preparation method of a compound of formula (I), which comprises the following steps:

1)式(Ⅷ)化合物与试剂A在酸作用下反应,得到式(Ⅶ)化合物:1) The compound of formula (Ⅷ) reacts with reagent A under the action of acid to obtain the compound of formula (Ⅶ):

Figure BDA0003231447290000021
Figure BDA0003231447290000021

其中,X为卤素;Wherein, X is a halogen;

2)式(Ⅶ)化合物与试剂B在金属试剂M作用下反应,得到式(Ⅵ)化合物:2) The compound of formula (VII) reacts with reagent B under the action of metal reagent M to obtain the compound of formula (VI):

Figure BDA0003231447290000022
Figure BDA0003231447290000022

3)式(Ⅵ)化合物与试剂C反应,得到式(Ⅴ)化合物:3) The compound of formula (Ⅵ) reacts with reagent C to obtain the compound of formula (Ⅴ):

Figure BDA0003231447290000023
Figure BDA0003231447290000023

4)式(Ⅴ)化合物与试剂D反应,得到式(Ⅳ)化合物:4) The compound of formula (Ⅴ) reacts with reagent D to obtain the compound of formula (Ⅳ):

Figure BDA0003231447290000024
Figure BDA0003231447290000024

5)式(Ⅳ)化合物与试剂E在有机碱作用下反应,得到式(Ⅲ)化合物:5) The compound of formula (Ⅳ) reacts with reagent E under the action of an organic base to obtain the compound of formula (Ⅲ):

Figure BDA0003231447290000025
Figure BDA0003231447290000025

6)式(Ⅲ)化合物与试剂F反应,得到式(Ⅱ)化合物:6) The compound of formula (Ⅲ) reacts with reagent F to obtain the compound of formula (Ⅱ):

Figure BDA0003231447290000031
Figure BDA0003231447290000031

7)式(Ⅱ)化合物与试剂G反应,得到式(Ⅰ)化合物:7) The compound of formula (II) reacts with reagent G to obtain the compound of formula (I):

Figure BDA0003231447290000032
Figure BDA0003231447290000032

优选地,根据本发明所述的式(Ⅰ)化合物的制备方法,步骤1)中,Preferably, in the preparation method of the compound of formula (I) according to the present invention, in step 1),

X为I、Br或Cl,所述试剂A为N-碘代丁二酰亚胺、I2、Br2、N-溴代丁二酰亚胺、二溴海因或N-氯 代丁二酰亚胺中的一种;优选地,X为I或Br,所述试剂A为N-碘代丁二酰亚胺、I2、Br2、N-溴代丁二 酰亚胺或二溴海因中的一种;更优选地,X为I,所述试剂A为N-碘代丁二酰亚胺;X is I, Br or Cl, and the reagent A is N-iodosuccinimide, I 2 , Br 2 , N-bromosuccinimide, dibromohydantoin or N-chlorobutanedi One of imides; preferably, X is I or Br, and the reagent A is N-iodosuccinimide, I 2 , Br 2 , N-bromosuccinimide or dibromo One of hydantoin; more preferably, X is I, and the reagent A is N-iodosuccinimide;

所述酸为有机酸,优选为三氟乙酸、三氯乙酸或醋酸中的一种,更优选为三氟乙酸;The acid is an organic acid, preferably one of trifluoroacetic acid, trichloroacetic acid or acetic acid, more preferably trifluoroacetic acid;

反应溶剂为N,N-二甲基甲酰胺、四氢呋喃或乙腈中的一种,优选为乙腈;The reaction solvent is one of N,N-dimethylformamide, tetrahydrofuran or acetonitrile, preferably acetonitrile;

反应温度为0~50℃,优选为20~30℃,更优选为25℃;The reaction temperature is 0-50°C, preferably 20-30°C, more preferably 25°C;

其中,所述式(Ⅷ)化合物、所述试剂A和所述酸的摩尔比为1:(1~1.5):(0.1~0.5),优选为1:1.3:0.2。Wherein, the molar ratio of the compound of formula (VIII), the reagent A and the acid is 1:(1-1.5):(0.1-0.5), preferably 1:1.3:0.2.

优选地,根据本发明所述的式(Ⅰ)化合物的制备方法,步骤2)中,所述试剂B为氘气、氘代酸 性试剂或重水中的一种。Preferably, in the preparation method of the compound of formula (I) according to the present invention, in step 2), the reagent B is one of deuterium gas, deuterated acidic reagent or heavy water.

进一步优选地,根据本发明所述的式(Ⅰ)化合物的制备方法,步骤2)中,所述式(Ⅶ)化合 物与所述氘气在所述金属试剂M和有机碱作用下反应;Further preferably, according to the preparation method of the compound of formula (I) according to the present invention, in step 2), the compound of formula (VII) reacts with the deuterium gas under the action of the metal reagent M and an organic base;

所述金属试剂M为钯催化剂,优选为钯碳;所述有机碱为三乙胺、N,N-二异丙基乙基胺、三甲胺、 氨气、氨水、DBU或吡啶中的一种,优选为三乙胺;反应溶剂为四氢呋喃、甲醇、乙醇、异丙醇或乙 酸乙酯中的一种,优选为四氢呋喃;反应压力为0.1~2MPa,优选为1.0MPa;反应温度为25~65℃, 优选为55~65℃;The metal reagent M is a palladium catalyst, preferably palladium carbon; the organic base is one of triethylamine, N,N-diisopropylethylamine, trimethylamine, ammonia gas, ammonia water, DBU or pyridine , preferably triethylamine; the reaction solvent is one of tetrahydrofuran, methanol, ethanol, isopropanol or ethyl acetate, preferably tetrahydrofuran; the reaction pressure is 0.1-2MPa, preferably 1.0MPa; the reaction temperature is 25-65 °C, preferably 55-65 °C;

其中,所述式(Ⅶ)化合物与所述钯碳干基的质量比为1:(0.01~0.2),所述式(Ⅶ)化合物与 所述有机碱的摩尔比为1:(1~3)。Wherein, the mass ratio of the compound of the formula (VII) to the dry base of the palladium carbon is 1:(0.01~0.2), and the molar ratio of the compound of the formula (VII) to the organic base is 1:(1~3 ).

进一步优选地,根据本发明所述的式(Ⅰ)化合物的制备方法,步骤2)中,所述式(Ⅶ)化合 物与所述氘代酸性试剂在所述金属试剂M作用下反应;Further preferably, according to the preparation method of the compound of formula (I) according to the present invention, in step 2), the compound of formula (VII) reacts with the deuterated acidic reagent under the action of the metal reagent M;

所述氘代酸性试剂为氘代盐酸、氘代硫酸、氘代醋酸、氘代三氟乙酸或氘代氯化铵中的一种;所 述金属试剂M为锌和/或铁;反应溶剂为超干四氢呋喃;反应温度为0~50℃,优选为20~30℃;The deuterated acid reagent is one of deuterated hydrochloric acid, deuterated sulfuric acid, deuterated acetic acid, deuterated trifluoroacetic acid or deuterated ammonium chloride; the metal reagent M is zinc and/or iron; the reaction solvent is Ultra-dry tetrahydrofuran; the reaction temperature is 0-50°C, preferably 20-30°C;

其中,所述式(Ⅶ)化合物、所述氘代酸性试剂与所述金属试剂M的摩尔比为1:(4.0~4.5):(4.0~6.0)。Wherein, the molar ratio of the compound of formula (VII), the deuterated acidic reagent and the metal reagent M is 1:(4.0-4.5):(4.0-6.0).

进一步优选地,根据本发明所述的式(Ⅰ)化合物的制备方法,步骤2)中,所述式(Ⅶ)化合 物与所述重水在所述金属试剂M和试剂B'作用下反应;Further preferably, according to the preparation method of the compound of formula (I) according to the present invention, in step 2), the compound of formula (VII) reacts with the heavy water under the action of the metal reagent M and reagent B';

所述金属试剂M为锌和/或铁;所述试剂B'为三氯氧磷、三氯化磷、三溴化磷、三氯化硼或三氯 化铝中的一种;反应溶剂为超干四氢呋喃;反应温度为0~50℃,优选为室温;The metal reagent M is zinc and/or iron; the reagent B' is one of phosphorus oxychloride, phosphorus trichloride, phosphorus tribromide, boron trichloride or aluminum trichloride; the reaction solvent is Ultra-dry tetrahydrofuran; the reaction temperature is 0-50°C, preferably room temperature;

其中,所述式(Ⅶ)化合物、所述重水、所述金属试剂M与试剂B'的摩尔比为1:(15~25):(2~4): (1~2)。Wherein, the molar ratio of the compound of formula (VII), the heavy water, the metal reagent M and the reagent B' is 1:(15-25):(2-4):(1-2).

优选地,根据本发明所述的式(Ⅰ)化合物的制备方法,步骤3)中,所述试剂C为三氯化硼和/ 或三溴化硼,反应溶剂为二氯甲烷,反应温度为-35~-25℃;Preferably, according to the preparation method of the compound of formula (I) according to the present invention, in step 3), the reagent C is boron trichloride and/or boron tribromide, the reaction solvent is dichloromethane, and the reaction temperature is -35~-25℃;

其中,所述式(Ⅵ)化合物与所述试剂C的摩尔比为1:(3~6)。Wherein, the molar ratio of the compound of formula (VI) to the reagent C is 1:(3-6).

优选地,根据本发明所述的式(Ⅰ)化合物的制备方法,步骤4)中,所述试剂D为N,N-二甲基 甲酰胺二甲基缩醛或N,N-二甲基甲酰胺二乙基缩醛,优选N,N-二甲基甲酰胺二甲基缩醛;反应溶剂为 四氢呋喃;反应温度为20~55℃,优选为45~55℃;Preferably, in the preparation method of the compound of formula (I) according to the present invention, in step 4), the reagent D is N,N-dimethylformamide dimethyl acetal or N,N-dimethyl Formamide diethyl acetal, preferably N,N-dimethylformamide dimethyl acetal; the reaction solvent is tetrahydrofuran; the reaction temperature is 20-55°C, preferably 45-55°C;

其中,所述式(Ⅴ)化合物与所述试剂D的摩尔比为1:(2~4)。Wherein, the molar ratio of the compound of formula (V) to the reagent D is 1:(2-4).

优选地,根据本发明所述的式(Ⅰ)化合物的制备方法,步骤5)中,所述试剂E为异丁酰氯、异 丁酸酐或异丁酸中的一种;Preferably, according to the preparation method of the compound of formula (I) according to the present invention, in step 5), the reagent E is one of isobutyryl chloride, isobutyric anhydride or isobutyric acid;

当所述试剂E为异丁酰氯或异丁酸酐时,所述式(Ⅳ)化合物与所述试剂E在有机碱和催化剂作用 下反应,所述有机碱为三乙胺和/或N,N-二异丙基乙基胺,优选三乙胺;所述催化剂为4-二甲基氨基吡 啶;反应溶剂为二氯甲烷;反应温度为5~30℃,优选为5~15℃;When the reagent E is isobutyryl chloride or isobutyric anhydride, the compound of formula (IV) reacts with the reagent E under the action of an organic base and a catalyst, and the organic base is triethylamine and/or N,N - diisopropylethylamine, preferably triethylamine; the catalyst is 4-dimethylaminopyridine; the reaction solvent is dichloromethane; the reaction temperature is 5-30°C, preferably 5-15°C;

其中,所述式(Ⅳ)化合物、所述试剂E、所述有机碱和所述催化剂的摩尔比为1:(3~5):(4~6): (0.01~0.1);Wherein, the molar ratio of the compound of formula (IV), the reagent E, the organic base and the catalyst is 1:(3-5):(4-6):(0.01-0.1);

当试剂E为异丁酸时,所述式(Ⅳ)化合物与所述试剂E在有机碱和缩合剂作用下反应,所述有机 碱为三乙胺和/或N,N-二异丙基乙基胺;所述缩合剂为二环己基碳二亚胺、1-(3-二甲氨基丙基)-3-乙基 碳二亚胺盐酸盐或1-羟基苯并三唑中的一种;反应溶剂为二氯甲烷;反应温度为5~30℃,反应温度 为5~15℃。When the reagent E is isobutyric acid, the compound of formula (IV) reacts with the reagent E under the action of an organic base and a condensing agent, and the organic base is triethylamine and/or N,N-diisopropyl Ethylamine; the condensing agent is dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride or 1-hydroxybenzotriazole One; the reaction solvent is dichloromethane; the reaction temperature is 5-30°C, and the reaction temperature is 5-15°C.

优选地,根据本发明所述的式(Ⅰ)化合物的制备方法,步骤6)中,所述试剂F为乙酸、三氟乙 酸、盐酸或水合肼中的一种,优选为乙酸;反应溶剂为乙醇、异丙醇、四氢呋喃或乙腈中的一种,优 选为乙醇;反应温度为0~55℃,优选为45~55℃;其中,所述(Ⅲ)化合物与所述试剂F的摩尔比为1: (15~25);Preferably, in the preparation method of the compound of formula (I) according to the present invention, in step 6), the reagent F is one of acetic acid, trifluoroacetic acid, hydrochloric acid or hydrazine hydrate, preferably acetic acid; the reaction solvent is One of ethanol, isopropanol, tetrahydrofuran or acetonitrile, preferably ethanol; the reaction temperature is 0 to 55°C, preferably 45 to 55°C; wherein, the molar ratio of the compound (Ⅲ) to the reagent F is 1: (15~25);

步骤7)中,所述试剂G为氢溴酸,反应温度为15~25℃;其中,所述式(Ⅱ)化合物与所述试剂 G的摩尔比为1:(1~1.2)。In step 7), the reagent G is hydrobromic acid, and the reaction temperature is 15-25°C; wherein, the molar ratio of the compound of formula (II) to the reagent G is 1:(1-1.2).

发明的效果The effect of the invention

本发明提供的抗病毒核苷类似物VV116的制备方法,反应条件温和,过程易控,操作简单,将有 助于该候选药物的进一步开发,并适合工业化大规模生产,高效、经济、实用,对预防和/或治疗 COVID-19具有重要意义。The preparation method of the antiviral nucleoside analog VV116 provided by the present invention has mild reaction conditions, easy control of the process, and simple operation, which will help the further development of the candidate drug and is suitable for large-scale industrial production. It is efficient, economical, and practical. It is of great significance for the prevention and/or treatment of COVID-19.

具体实施方式Detailed ways

以下将详细说明本发明的各种示例性实施例、特征和方面。在这里专用的词“示例性”意为“用作 例子、实施例或说明性”。这里作为“示例性”所说明的任何实施例不必解释为优于或好于其它实施例。Various exemplary embodiments, features, and aspects of the invention are described in detail below. The word "exemplary" as used herein means "serving as an example, embodiment, or illustration." Any embodiment described herein as "exemplary" is not necessarily to be construed as superior or better than other embodiments.

另外,为了更好地说明本发明,在下文的具体实施方式中给出了众多的具体细节。本领域技术人 员应当理解,没有某些具体细节,本发明同样可以实施。在另外一些实例中,对于本领域技术人员熟 知的方法、手段、器材和步骤未作详细描述,以便于凸显本发明的主旨。In addition, in order to better illustrate the present invention, numerous specific details are given in the specific embodiments below. It will be understood by those skilled in the art that the present invention may be practiced without certain of the specific details. In other instances, methods, means, devices and steps well known to those skilled in the art are not described in detail in order to highlight the gist of the present invention.

如无特殊声明,本说明书中,未注明具体条件者,按照常规条件或制造商建议的条件进行。所用 试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规产品。If there is no special statement, in this manual, if no specific conditions are indicated, follow the general conditions or the conditions suggested by the manufacturer. The reagents or instruments used were not indicated by the manufacturer, and they were all commercially available conventional products.

本说明书中,所使用的单位均为国际标准单位,并且本发明中出现的数值、数值范围,均应当理 解为包含了工业生产中所不可避免的系统性误差。In this specification, the units used are all international standard units, and the numerical values and numerical ranges appearing in the present invention should be understood as including inevitable systematic errors in industrial production.

本说明书中,使用“可以”表示的含义包括了进行某种处理以及不进行某种处理两方面的含义。In this specification, the meaning expressed by "may" includes the meaning of performing certain processing and not performing certain processing.

本说明书中,所提及的“一些具体/优选的实施方案”、“另一些具体/优选的实施方案”、“实施方案” 等是指所描述的与该实施方案有关的特定要素(例如,特征、结构、性质和/或特性)包括在此处所述的 至少一种实施方案中,并且可存在于其它实施方案中或者可不存在于其它实施方案中。另外,应理解, 所述要素可以任何合适的方式组合在各种实施方案中。In this specification, references to "some specific/preferred embodiments", "other specific/preferred embodiments", "embodiments" and the like refer to specific elements described in relation to the embodiments (for example, A feature, structure, property and/or characteristic) is included in at least one embodiment described herein and may or may not be present in other embodiments. In addition, it is to be understood that the described elements may be combined in any suitable manner in the various embodiments.

本发明提供本发明提供一种式(Ⅰ)化合物的制备方法,The present invention provides the present invention provides a preparation method of the compound of formula (I),

Figure BDA0003231447290000051
Figure BDA0003231447290000051

包括以下步骤:Include the following steps:

1)式(Ⅷ)化合物与试剂A在酸作用下反应,得到式(Ⅶ)化合物:1) The compound of formula (Ⅷ) reacts with reagent A under the action of acid to obtain the compound of formula (Ⅶ):

Figure BDA0003231447290000052
Figure BDA0003231447290000052

其中,X为卤素;Wherein, X is a halogen;

2)式(Ⅶ)化合物与试剂B在金属试剂M作用下反应,得到式(Ⅵ)化合物:2) The compound of formula (VII) reacts with reagent B under the action of metal reagent M to obtain the compound of formula (VI):

Figure BDA0003231447290000053
Figure BDA0003231447290000053

3)式(Ⅵ)化合物与试剂C反应,得到式(Ⅴ)化合物:3) The compound of formula (Ⅵ) reacts with reagent C to obtain the compound of formula (Ⅴ):

Figure BDA0003231447290000054
Figure BDA0003231447290000054

4)式(Ⅴ)化合物与试剂D反应,得到式(Ⅳ)化合物:4) The compound of formula (Ⅴ) reacts with reagent D to obtain the compound of formula (Ⅳ):

Figure BDA0003231447290000061
Figure BDA0003231447290000061

5)式(Ⅳ)化合物与试剂E在有机碱作用下反应,得到式(Ⅲ)化合物:5) The compound of formula (Ⅳ) reacts with reagent E under the action of an organic base to obtain the compound of formula (Ⅲ):

Figure BDA0003231447290000062
Figure BDA0003231447290000062

6)式(Ⅲ)化合物与试剂F反应,得到式(Ⅱ)化合物:6) The compound of formula (Ⅲ) reacts with reagent F to obtain the compound of formula (Ⅱ):

Figure BDA0003231447290000063
Figure BDA0003231447290000063

7)式(Ⅱ)化合物与试剂G反应,得到式(Ⅰ)化合物:7) The compound of formula (II) reacts with reagent G to obtain the compound of formula (I):

Figure BDA0003231447290000064
Figure BDA0003231447290000064

上述实施方案中:In the above embodiment:

步骤1)step 1)

在本发明一些具体的实施方案中,X为I、Br或Cl,试剂A为N-碘代丁二酰亚胺(NIS)、I2、Br2、 N-溴代丁二酰亚胺(NBS)、二溴海因或N-氯代丁二酰亚胺(NCS)中的一种。In some specific embodiments of the present invention, X is I, Br or Cl, reagent A is N-iodosuccinimide (NIS), I 2 , Br 2 , N-bromosuccinimide ( NBS), dibromohydantoin or N-chlorosuccinimide (NCS).

在本发明一些优选的实施方案中,X为I或Br,试剂A为N-碘代丁二酰亚胺、I2、Br2、N-溴代丁二 酰亚胺或二溴海因中的一种。In some preferred embodiments of the present invention, X is I or Br, and reagent A is N-iodosuccinimide, I 2 , Br 2 , N-bromosuccinimide or dibromohydantoin kind of.

在本发明一些更优选的实施方案中,X为I,试剂A为N-碘代丁二酰亚胺。In some more preferred embodiments of the invention, X is I and reagent A is N-iodosuccinimide.

在本发明一些具体的实施方案中,酸为有机酸。在本发明一些优选的实施方案中,有机酸为三氟 乙酸、三氯乙酸或醋酸中的一种,更优选为三氟乙酸。In some specific embodiments of the invention, the acid is an organic acid. In some preferred embodiments of the present invention, the organic acid is one of trifluoroacetic acid, trichloroacetic acid or acetic acid, more preferably trifluoroacetic acid.

在本发明一些具体的实施方案中,反应溶剂为N,N-二甲基甲酰胺、四氢呋喃或乙腈中的一种,优 选为乙腈。In some specific embodiments of the present invention, the reaction solvent is one of N,N-dimethylformamide, tetrahydrofuran or acetonitrile, preferably acetonitrile.

在本发明一些具体的实施方案中,反应温度为0~50℃,优选为20~30℃,更优选为25℃。示例 性地,反应温度可以为0℃、10℃、20℃、25℃、30℃、40℃、50℃等。In some specific embodiments of the present invention, the reaction temperature is 0-50°C, preferably 20-30°C, more preferably 25°C. Exemplarily, the reaction temperature may be 0°C, 10°C, 20°C, 25°C, 30°C, 40°C, 50°C, etc.

在本发明一些具体的实施方案中,反应时间为3~5小时,优选为4小时。In some specific embodiments of the present invention, the reaction time is 3-5 hours, preferably 4 hours.

其中,式(Ⅷ)化合物、试剂A和酸的摩尔比为1:(1~1.5):(0.1~0.5),示例性地,式(Ⅷ)化 合物、试剂A和酸的摩尔比可以为1:1:0.1,1:1.25:0.2、1:1.3:0.2,1:1.35:0.2、1:1.5:0.5等。在本发明一 些优选的实施方案中,式(Ⅷ)化合物、试剂A和酸的摩尔比为1:1.3:0.2。Wherein, the molar ratio of formula (Ⅷ) compound, reagent A and acid is 1:(1~1.5):(0.1~0.5), illustratively, the molar ratio of formula (Ⅷ) compound, reagent A and acid can be 1 :1:0.1, 1:1.25:0.2, 1:1.3:0.2, 1:1.35:0.2, 1:1.5:0.5, etc. In some preferred embodiments of the present invention, the molar ratio of the compound of formula (VIII), reagent A and acid is 1:1.3:0.2.

步骤2)Step 2)

该步骤中,试剂B为氘气、氘代酸性试剂或重水中的一种,均可获得较高的氘代率。In this step, reagent B is one of deuterium gas, deuterated acidic reagent or heavy water, all of which can obtain higher deuterated rate.

在本发明一些具体的实施方案中,所选用试剂B为氘气,式(Ⅶ)化合物与氘气在金属试剂M和 有机碱作用下反应得到氘代产物(Ⅵ)。In some specific embodiments of the present invention, the selected reagent B is deuterium gas, and the compound of formula (VII) reacts with deuterium gas under the action of the metal reagent M and an organic base to obtain the deuterated product (VI).

上述金属试剂M为钯催化剂,优选为钯碳;有机碱为三乙胺、N,N-二异丙基乙基胺、三甲胺、氨 气、氨水、DBU或吡啶中的一种,优选为三乙胺;反应溶剂为四氢呋喃、甲醇、乙醇、异丙醇或乙酸 乙酯中的一种,优选为四氢呋喃;反应压力为0.1~2MPa,优选为1.0MPa;反应温度为25~65℃,优 选为55~65℃,示例性地,反应温度可以为25℃、35℃、45℃、50℃、55℃、60℃、65℃等; 反应时间为0.5~2.0小时,优选为1~1.5小时。The above metal reagent M is a palladium catalyst, preferably palladium carbon; the organic base is one of triethylamine, N,N-diisopropylethylamine, trimethylamine, ammonia gas, ammonia water, DBU or pyridine, preferably Triethylamine; the reaction solvent is one of tetrahydrofuran, methanol, ethanol, isopropanol or ethyl acetate, preferably tetrahydrofuran; the reaction pressure is 0.1-2MPa, preferably 1.0MPa; the reaction temperature is 25-65°C, preferably 55-65°C. Exemplarily, the reaction temperature can be 25°C, 35°C, 45°C, 50°C, 55°C, 60°C, 65°C, etc.; the reaction time is 0.5-2.0 hours, preferably 1-1.5 hours .

其中,式(Ⅶ)化合物与钯碳干基的质量比为1:(0.01~0.2),示例性地,其质量比可以为1:0.01、 1:0.03、1:0.05、1:0.08、1:0.1、1:0.12、1:0.15、1:0.2等,优选为1:0.03。该钯碳为常规市售湿钯碳,含 水约55%,钯含量为5~10%。Wherein, the mass ratio of the compound of formula (VII) to palladium carbon dry base is 1:(0.01~0.2), for example, the mass ratio can be 1:0.01, 1:0.03, 1:0.05, 1:0.08, 1 :0.1, 1:0.12, 1:0.15, 1:0.2, etc., preferably 1:0.03. The palladium carbon is conventional commercially available wet palladium carbon, containing about 55% water, and the palladium content is 5-10%.

式(Ⅶ)化合物与有机碱的摩尔比为1:(1~3),优选为1:2。The molar ratio of the compound of formula (VII) to the organic base is 1:(1-3), preferably 1:2.

在本发明一些具体的实施方案中,所用试剂B为氘代酸性试剂,式(Ⅶ)化合物与氘代酸性试剂 在金属试剂M作用下反应得到氘代产物(Ⅵ)。In some specific embodiments of the present invention, the reagent B used is a deuterated acidic reagent, and the compound of formula (VII) reacts with the deuterated acidic reagent under the action of the metal reagent M to obtain the deuterated product (VI).

上述氘代酸性试剂为氘代盐酸、氘代硫酸、氘代醋酸、氘代三氟乙酸或氘代氯化铵中的一种,优 选氘代盐酸;金属试剂M为锌和/或铁,优选锌;反应溶剂为超干四氢呋喃;反应温度为0~50℃,优 选地为20~30℃,示例性地,反应温度为0℃、10℃、20℃、25℃、30℃、40℃、50℃等;反 应时间为0.1~10小时,优选为0.2~4.0小时。The above-mentioned deuterated acidic reagent is one of deuterated hydrochloric acid, deuterated sulfuric acid, deuterated acetic acid, deuterated trifluoroacetic acid or deuterated ammonium chloride, preferably deuterated hydrochloric acid; metal reagent M is zinc and/or iron, preferably Zinc; the reaction solvent is ultra-dry tetrahydrofuran; the reaction temperature is 0-50°C, preferably 20-30°C, for example, the reaction temperature is 0°C, 10°C, 20°C, 25°C, 30°C, 40°C, 50°C, etc.; the reaction time is 0.1 to 10 hours, preferably 0.2 to 4.0 hours.

其中,式(Ⅶ)化合物、氘代酸性试剂和金属试剂M的摩尔比为1:(4.0~4.5):(4.0~6.0),示例 性地,其摩尔比可以为1:4.0:4.0,1:4.14:5.0,1:4.5:6.0等,优选为1:4.14:5.0。Wherein, the molar ratio of the compound of formula (VII), the deuterated acidic reagent and the metal reagent M is 1:(4.0~4.5):(4.0~6.0), illustratively, the molar ratio can be 1:4.0:4.0,1 :4.14:5.0, 1:4.5:6.0, etc., preferably 1:4.14:5.0.

在本发明一些具体的实施方案中,所用试剂B为重水,式(Ⅶ)化合物与重水在金属试剂M和试 剂B'作用下反应得到氘代产物(Ⅵ)。In some specific embodiments of the present invention, the reagent B used is heavy water, and the compound of formula (VII) reacts with heavy water under the action of the metal reagent M and reagent B' to obtain the deuterated product (VI).

上述金属试剂M为锌和/或铁,优选锌;试剂B'选自与重水反应可生成酸的物质,包括三氯氧磷、 三氯化磷、三溴化磷、三氯化硼和三氯化铝中的一种,优选三氯氧磷;反应溶剂为超干四氢呋喃;反 应温度为0~50℃,优选室温;反应时间为0.1~10小时,优选为0.2~4.0小时。Above-mentioned metal reagent M is zinc and/or iron, preferably zinc; Reagent B' is selected from the material that can generate acid with heavy water reaction, comprises phosphorus oxychloride, phosphorus trichloride, phosphorus tribromide, boron trichloride and trichloride One of aluminum chloride, preferably phosphorus oxychloride; the reaction solvent is ultra-dry tetrahydrofuran; the reaction temperature is 0-50°C, preferably room temperature; the reaction time is 0.1-10 hours, preferably 0.2-4.0 hours.

其中,式(Ⅶ)化合物、重水、金属试剂M和试剂B'的摩尔比为1:(15~25):(2~4):(1~2), 示例性地,其摩尔比可以为1:15:2:1,1:20:3:1.5,1:25:4:2等,优选为1:20:3:1.5。Wherein, the molar ratio of formula (VII) compound, heavy water, metal reagent M and reagent B' is 1:(15~25):(2~4):(1~2), illustratively, its molar ratio can be 1:15:2:1, 1:20:3:1.5, 1:25:4:2, etc., preferably 1:20:3:1.5.

步骤3)step 3)

该步骤中,试剂C为三氯化硼或三溴化硼,优选三氯化硼;反应溶剂为二氯甲烷;反应温度为 -35~-25℃,优选为-30~-25℃,示例性地,反应温度可以为-35℃、-30℃、-25℃等;反应时间为0.1~3 小时,优选为0.2~1小时。In this step, the reagent C is boron trichloride or boron tribromide, preferably boron trichloride; the reaction solvent is dichloromethane; the reaction temperature is -35~-25°C, preferably -30~-25°C, for example Typically, the reaction temperature can be -35°C, -30°C, -25°C, etc.; the reaction time is 0.1-3 hours, preferably 0.2-1 hour.

其中,式(Ⅵ)化合物与试剂C的摩尔比为1:(3~6),示例性地,其摩尔比可以为1:3、1:4、1:4.4、 1:5等,优选为1:4、1:4.4。Wherein, the molar ratio of the compound of formula (VI) to reagent C is 1:(3-6), for example, the molar ratio can be 1:3, 1:4, 1:4.4, 1:5, etc., preferably 1:4, 1:4.4.

待反应完全后,加入甲醇将反应淬灭,升温至10~20℃,搅拌数小时,滴加正庚烷有固体析出, 过滤,将滤饼悬浮于水中,然后用10wt%碳酸钠溶液将pH值调至8~9,过滤得到粗品,用乙腈加热打 浆,得到式(Ⅴ)化合物纯品。After the reaction is complete, add methanol to quench the reaction, raise the temperature to 10-20°C, stir for several hours, add n-heptane dropwise and solids will precipitate out, filter, suspend the filter cake in water, and then use 10wt% sodium carbonate solution to adjust the pH The value was adjusted to 8-9, and the crude product was obtained by filtration, and heated and beaten with acetonitrile to obtain the pure product of the compound of formula (Ⅴ).

其中,式(Ⅵ)化合物重量份与甲醇体积份的比为1:(5~15),示例性地,可以为1:5、1:10、1:15 等;式(Ⅵ)化合物重量份与正庚烷体积份的比为1:(5~15),示例性地,可以为1:5、1:10、1:15等; 式(Ⅵ)化合物重量份与乙腈体积份的比为1:(1~10),示例性地,可以为1:5、1:4、1:7.5、1:10等。 其中,重量份与体积份的对应关系为g/mL。Wherein, the ratio of the weight part of the compound of formula (VI) to the volume part of methanol is 1: (5-15), for example, it can be 1:5, 1:10, 1:15, etc.; the weight part of the compound of formula (VI) The ratio of the volume parts of n-heptane is 1: (5-15), for example, it can be 1:5, 1:10, 1:15, etc.; the ratio of the weight parts of the compound of formula (VI) to the volume parts of acetonitrile is 1:(1-10), for example, may be 1:5, 1:4, 1:7.5, 1:10, etc. Wherein, the corresponding relationship between parts by weight and parts by volume is g/mL.

步骤4)Step 4)

该步骤中,试剂D为N,N-二甲基甲酰胺二甲基缩醛或N,N-二甲基甲酰胺二乙基缩醛,优选为N,N- 二甲基甲酰胺二甲基缩醛;反应溶剂为四氢呋喃;反应温度为20~55℃,优选为45~55℃,示例性地, 反应温度可以为45℃、50℃、55℃等;反应时间为3~8小时,示例性地,反应时间为3小时,4小时, 5小时,6小时,7小时,8小时等,优选5小时。In this step, the reagent D is N,N-dimethylformamide dimethyl acetal or N,N-dimethylformamide diethyl acetal, preferably N,N-dimethylformamide dimethyl acetal base acetal; the reaction solvent is tetrahydrofuran; the reaction temperature is 20-55°C, preferably 45-55°C, for example, the reaction temperature can be 45°C, 50°C, 55°C, etc.; the reaction time is 3-8 hours, Exemplarily, the reaction time is 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, etc., preferably 5 hours.

其中,式(Ⅴ)化合物与试剂D的摩尔比为1:(2~4),优选为1:(3~4),示例性地,其摩尔比 为1:3,1:3.5,1:4等,优选为1:3.5。Wherein, the molar ratio of the compound of formula (V) to reagent D is 1:(2-4), preferably 1:(3-4), for example, the molar ratio is 1:3, 1:3.5, 1: 4 etc., preferably 1:3.5.

待反应完全后,加入甲醇淬灭反应,浓缩后加入乙酸乙酯和正庚烷的混合溶剂,在15~25℃下打 浆,搅拌1~2小时,过滤,滤饼用正庚烷淋洗,得到式(Ⅳ)化合物。After the reaction is complete, add methanol to quench the reaction, add a mixed solvent of ethyl acetate and n-heptane after concentration, beat at 15-25°C, stir for 1-2 hours, filter, and rinse the filter cake with n-heptane to obtain Compounds of formula (IV).

其中,混合溶剂中,乙酸乙酯和正庚烷的体积比为1:(2~10)。Wherein, in the mixed solvent, the volume ratio of ethyl acetate and n-heptane is 1:(2~10).

步骤5)Step 5)

该步骤中,试剂E为异丁酰氯、异丁酸酐或异丁酸中的一种。In this step, the reagent E is one of isobutyryl chloride, isobutyric anhydride or isobutyric acid.

在本发明一些具体的实施方案中,所用试剂E为异丁酰氯或异丁酸酐,式(Ⅳ)化合物与异丁酰 氯或异丁酸酐在有机碱和催化剂作用下反应,优选选用异丁酸酐。In some specific embodiments of the present invention, the reagent E used is isobutyryl chloride or isobutyric anhydride, and the compound of formula (IV) reacts with isobutyryl chloride or isobutyric anhydride under the action of an organic base and a catalyst, preferably isobutyryl anhydride.

上述有机碱为三乙胺和/或N,N-二异丙基乙基胺,优选三乙胺;催化剂为4-二甲基氨基吡啶;反应 溶剂为二氯甲烷;反应温度为5~30℃,优选为5~15℃,示例性地,反应温度为5℃、10℃、15℃ 等;反应时间为1~2小时。The above-mentioned organic base is triethylamine and/or N,N-diisopropylethylamine, preferably triethylamine; the catalyst is 4-dimethylaminopyridine; the reaction solvent is dichloromethane; the reaction temperature is 5-30 °C, preferably 5-15 °C, for example, the reaction temperature is 5 °C, 10 °C, 15 °C, etc.; the reaction time is 1-2 hours.

其中,式(Ⅳ)化合物、异丁酸酐、三乙胺和4-二甲基吡啶的摩尔比为1:(3~5):(4~6):(0.01~0.1), 示例性地,其摩尔比可以为1:3:4:0.01,1:4:5:0.05,1:5:6:0.1等,优选1:4:5:0.05。Wherein, the molar ratio of the compound of formula (IV), isobutyric anhydride, triethylamine and 4-lutidine is 1:(3~5):(4~6):(0.01~0.1), exemplarily, Its molar ratio can be 1:3:4:0.01, 1:4:5:0.05, 1:5:6:0.1, etc., preferably 1:4:5:0.05.

在本发明一些具体的实施方案中,所用试剂E为异丁酸,式(Ⅳ)化合物与异丁酸在有机碱和缩 合剂作用下反应。In some specific embodiments of the present invention, the reagent E used is isobutyric acid, and the compound of formula (IV) reacts with isobutyric acid under the action of an organic base and a condensing agent.

上述有机碱为三乙胺和/或N,N-二异丙基乙基胺,优选三乙胺;缩合剂为二环己基碳二亚胺、1-(3- 二甲氨基丙基)-3-乙基碳二亚胺盐酸盐或1-羟基苯并三唑中的一种;反应温度为5~30℃,优选5~15℃, 示例性地,反应温度可以为5℃、10℃、15℃等;反应时间为1~2小时。The above-mentioned organic base is triethylamine and/or N,N-diisopropylethylamine, preferably triethylamine; the condensing agent is dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)- One of 3-ethylcarbodiimide hydrochloride or 1-hydroxybenzotriazole; the reaction temperature is 5-30°C, preferably 5-15°C. Exemplarily, the reaction temperature can be 5°C, 10 °C, 15 °C, etc.; the reaction time is 1 to 2 hours.

步骤6)Step 6)

该步骤中,试剂F为乙酸、三氟乙酸、盐酸或水合肼中的一种,优选乙酸;反应溶剂为乙醇、异 丙醇、四氢呋喃或乙腈中的一种,优选乙醇;反应温度为0~55℃,优选45~55℃;反应时间为8~10 小时。In this step, the reagent F is one of acetic acid, trifluoroacetic acid, hydrochloric acid or hydrazine hydrate, preferably acetic acid; the reaction solvent is one of ethanol, isopropanol, tetrahydrofuran or acetonitrile, preferably ethanol; the reaction temperature is 0~ 55°C, preferably 45-55°C; the reaction time is 8-10 hours.

其中,(Ⅲ)化合物与试剂F的摩尔比为1:(15~25),示例性地,其摩尔比可以为1:15,1:20, 1:25等,优选为1:20。Wherein, the molar ratio of compound (III) to reagent F is 1:(15-25), for example, the molar ratio can be 1:15, 1:20, 1:25, etc., preferably 1:20.

步骤7)Step 7)

该步骤中,试剂G为氢溴酸,优选48%溴化氢水溶液;反应溶剂为乙腈;反应温度为15~25℃, 反应时间为0.5~1.5小时。In this step, the reagent G is hydrobromic acid, preferably 48% aqueous hydrogen bromide; the reaction solvent is acetonitrile; the reaction temperature is 15-25° C., and the reaction time is 0.5-1.5 hours.

其中,式(Ⅱ)化合物与氢溴酸的摩尔比为1:(1~1.2)。Wherein, the molar ratio of the compound of formula (II) to hydrobromic acid is 1:(1-1.2).

待反应结束,打浆纯化,所用溶剂为甲基叔丁基醚、丙酮、乙酸乙酯或异丙醇中的一种,优选甲 基叔丁基醚。After the reaction is finished, beating and purifying, the solvent used is one of methyl tert-butyl ether, acetone, ethyl acetate or Virahol, preferably methyl tert-butyl ether.

其中,式(Ⅱ)化合物重量份与甲基叔丁基醚体积份的比为1:(1~10),重量份与体积份的对应 关系为g/mL。Wherein, the ratio of the weight part of the compound of formula (II) to the volume part of methyl tert-butyl ether is 1: (1-10), and the corresponding relationship between the weight part and the volume part is g/mL.

在另一些优选的实施方案中,本发明提供的式(Ⅰ)化合物的制备方法,包括以下步骤:In other preferred embodiments, the preparation method of the compound of formula (I) provided by the present invention comprises the following steps:

1)将式(Ⅷ)化合物加至反应溶剂中,氮气保护,控温在25℃,分批加入试剂A,然后加入酸, 反应得到式(Ⅶ)化合物。1) The compound of formula (Ⅷ) is added to the reaction solvent, under nitrogen protection, the temperature is controlled at 25°C, the reagent A is added in batches, and then the acid is added to react to obtain the compound of formula (VII).

2)将式(Ⅶ)化合物加至反应溶剂中,然后依次加入三乙胺和钯碳,氮气置换,通入氘气,加 压至1.0MPa左右,升温至55~65℃,反应得到式(Ⅵ)化合物。2) Add the compound of formula (VII) to the reaction solvent, then add triethylamine and palladium carbon in sequence, replace with nitrogen, pass in deuterium gas, pressurize to about 1.0MPa, heat up to 55-65°C, and react to obtain the formula ( VI) Compounds.

3)将式(Ⅵ)化合物溶于二氯甲烷中,氮气保护,降温至-35~-25℃,滴加三氯化硼的二氯甲烷 溶液;待反应完全,加入甲醇将反应淬灭,然后升温至10~20℃,搅拌数小时,滴加正庚烷,滴加结 束有固体析出,过滤,将滤饼悬浮于水中,然后用10wt%碳酸钠溶液将pH调至8~9,过滤,得到式(Ⅴ) 化合物粗品,将粗品用乙腈加热打浆,得到式(Ⅴ)化合物纯品。3) Dissolve the compound of formula (Ⅵ) in dichloromethane, under nitrogen protection, cool down to -35~-25°C, add a solution of boron trichloride in dichloromethane dropwise; when the reaction is complete, add methanol to quench the reaction, Then heat up to 10-20°C, stir for several hours, add n-heptane dropwise, solids precipitate out at the end of the dropwise addition, filter, suspend the filter cake in water, then adjust the pH to 8-9 with 10wt% sodium carbonate solution, filter , to obtain a crude product of the compound of formula (Ⅴ), which was heated and beaten with acetonitrile to obtain a pure product of the compound of formula (Ⅴ).

4)将式(Ⅴ)化合物和试剂D加至四氢呋喃中,氮气保护,升温至45~55℃,待式(Ⅴ)化合 物完全转化,将反应液浓缩,然后加入甲醇打浆,将反应液浓缩,加入乙酸乙酯和正庚烷的混合溶剂 打浆,得到式(Ⅳ)化合物。4) Add the compound of formula (Ⅴ) and reagent D into tetrahydrofuran, protect it with nitrogen, and raise the temperature to 45-55°C. After the compound of formula (Ⅴ) is completely converted, concentrate the reaction solution, then add methanol for beating, and concentrate the reaction solution. Add a mixed solvent of ethyl acetate and n-heptane to make a slurry to obtain the compound of formula (IV).

5)将式(Ⅳ)化合物加至二氯甲烷中,然后依次加入三乙胺、4-二甲氨基吡啶和异丁酸酐,反 应得到式(Ⅲ)化合物。5) Add the compound of formula (IV) into dichloromethane, then add triethylamine, 4-dimethylaminopyridine and isobutyric anhydride in sequence, and react to obtain the compound of formula (III).

6)将式(Ⅲ)化合物加至溶剂中,然后加入试剂F,升温至45~55℃反应,得到式(Ⅱ)化合物。6) Add the compound of formula (III) to the solvent, then add reagent F, heat up to 45-55°C for reaction, and obtain the compound of formula (II).

7)将式(Ⅱ)化合物加至溶剂中,然后加入活性炭和无水硫酸钠,过滤,将滤液冷却至15℃以 下,滴加氢溴酸,然后在15~25℃下搅拌1小时,浓缩至小体积,并用甲基叔丁基醚回流打浆,然后 冷却过滤得式(Ⅰ)化合物。7) Add the compound of formula (II) to the solvent, then add activated carbon and anhydrous sodium sulfate, filter, cool the filtrate to below 15°C, add hydrobromic acid dropwise, then stir at 15-25°C for 1 hour, concentrate to a small volume, and refluxed with methyl tert-butyl ether to make a slurry, then cooled and filtered to obtain the compound of formula (I).

在另一些优选的实施方案中,步骤2)可以替换为,将式(Ⅶ)化合物加至四氢呋喃中,然后依 次加入重水、锌粉和三氯氧磷,反应得到式(Ⅵ)化合物。In other preferred embodiments, step 2) can be replaced by adding the compound of formula (VII) to tetrahydrofuran, and then adding heavy water, zinc powder and phosphorus oxychloride in sequence to react to obtain the compound of formula (VI).

在另一些优选的实施方案中,步骤2)可以替换为,将式(Ⅶ)化合物加至四氢呋喃中,然后依 次加入氘代盐酸和锌粉,反应得到式(Ⅵ)化合物。In other preferred embodiments, step 2) can be replaced by adding the compound of formula (VII) to tetrahydrofuran, and then adding deuterated hydrochloric acid and zinc powder in sequence to react to obtain the compound of formula (VI).

对于上述步骤1)~7)中,For the above steps 1) to 7),

在本发明一些更优选的实施方案中,步骤1)中,反应溶剂为乙腈。In some more preferred embodiments of the present invention, in step 1), the reaction solvent is acetonitrile.

在本发明一些更优选的实施方案中,步骤1)中,X为I,试剂A为N-碘代丁二酰亚胺。In some more preferred embodiments of the present invention, in step 1), X is I, and reagent A is N-iodosuccinimide.

在本发明一些更优选的实施方案中,步骤1)中,酸为三氟乙酸。In some more preferred embodiments of the present invention, in step 1), the acid is trifluoroacetic acid.

在本发明一些更优选的实施方案中,步骤1)中,式(Ⅷ)化合物、试剂A、酸的摩尔比为1:1.3:0.2。In some more preferred embodiments of the present invention, in step 1), the molar ratio of the compound of formula (VIII), reagent A, and acid is 1:1.3:0.2.

在本发明一些更优选的实施方案中,步骤2)中,反应溶剂为四氢呋喃。In some more preferred embodiments of the present invention, in step 2), the reaction solvent is tetrahydrofuran.

在本发明一些更优选的实施方案中,步骤2)中,式(Ⅶ)化合物和三乙胺的摩尔比为1:2。In some more preferred embodiments of the present invention, in step 2), the molar ratio of the compound of formula (VII) to triethylamine is 1:2.

在本发明一些更优选的实施方案中,步骤2)中,以钯碳干基质量计算,式(Ⅶ)化合物和钯碳 的重量比为1:0.03(以干基质量计)。In some more preferred embodiments of the present invention, in step 2), the weight ratio of the compound of formula (VII) to palladium on carbon is 1:0.03 (on a dry basis) based on the dry basis of palladium on carbon.

在本发明一些更优选的实施方案中,步骤3)中,式(Ⅵ)化合物和三氯化硼的摩尔比为1:4。In some more preferred embodiments of the present invention, in step 3), the molar ratio of the compound of formula (VI) to boron trichloride is 1:4.

在本发明一些更优选的实施方案中,步骤3)中,式(Ⅵ)化合物重量份与甲醇体积份的比为1: (5~15),示例性地,可以为1:5、1:10、1:15等;其中,重量份与体积份的对应关系为g/mL。In some more preferred embodiments of the present invention, in step 3), the ratio of the weight part of the compound of formula (VI) to the volume part of methanol is 1: (5-15), for example, it can be 1:5, 1: 10, 1:15, etc.; wherein, the corresponding relationship between parts by weight and parts by volume is g/mL.

在本发明一些更优选的实施方案中,步骤3)中,式(Ⅵ)化合物重量份与正庚烷体积份的比为 1:(5~15),示例性地,可以为1:5、1:10、1:15等;其中,重量份与体积份的对应关系为g/mL。In some more preferred embodiments of the present invention, in step 3), the ratio of the weight part of the compound of formula (VI) to the volume part of n-heptane is 1: (5-15), for example, it can be 1:5, 1:10, 1:15, etc.; wherein, the corresponding relationship between parts by weight and parts by volume is g/mL.

在本发明一些更优选的实施方案中,步骤3)中,式(Ⅵ)化合物重量份与乙腈体积份的比为1: (1~10),示例性地,可以为1:5、1:7.5、1:10等;其中,重量份与体积份的对应关系为g/mL。In some more preferred embodiments of the present invention, in step 3), the ratio of the weight part of the compound of formula (VI) to the volume part of acetonitrile is 1: (1-10), for example, it can be 1:5, 1: 7.5, 1:10, etc.; wherein, the corresponding relationship between parts by weight and parts by volume is g/mL.

在本发明一些更优选的实施方案中,步骤4)中,试剂D为N,N-二甲基甲酰胺二甲缩醛。In some more preferred embodiments of the present invention, in step 4), the reagent D is N,N-dimethylformamide dimethyl acetal.

在本发明一些更优选的实施方案中,步骤4)中,打浆所用乙酸乙酯和正庚烷的体积比为1:(2~10)。In some more preferred embodiments of the present invention, in step 4), the volume ratio of ethyl acetate and n-heptane used for beating is 1:(2-10).

在本发明一些更优选的实施方案中,步骤5)中,式(Ⅳ)化合物、异丁酸酐、三乙胺和4-二甲 氨基吡啶的摩尔比为1:(3~5):(4~6):(0.01~0.1)。In some more preferred embodiments of the present invention, in step 5), the molar ratio of the compound of formula (IV), isobutyric anhydride, triethylamine and 4-dimethylaminopyridine is 1:(3~5):(4 ~6): (0.01~0.1).

在本发明一些更优选的实施方案中,步骤6)中,溶剂为乙醇,试剂F为乙酸。In some more preferred embodiments of the present invention, in step 6), the solvent is ethanol, and the reagent F is acetic acid.

在本发明一些更优选的实施方案中,步骤7)中,式(Ⅱ)化合物重量份与甲基叔丁基醚体积份 的比为1:(1~10),重量份与体积份的对应关系为g/mL。In some more preferred embodiments of the present invention, in step 7), the ratio of the weight part of the compound of formula (II) to the volume part of methyl tert-butyl ether is 1: (1-10), and the corresponding ratio of the weight part to the volume part The relationship is g/mL.

实施例1Example 1

1)式(Ⅶ)化合物制备:1) Preparation of formula (Ⅶ) compound:

Figure BDA0003231447290000101
Figure BDA0003231447290000101

向30L反应器中加入式(Ⅷ)化合物(4.5kg,1eq)、乙腈(22.5L,5V),氮气保护下,控温 25℃,分批加入NIS(2.34kg,1.3eq),加毕,继续控温滴加三氟乙酸(183.9g,0.2eq),滴毕,在 25℃下反应4h,TLC显示原料已经反应完全。浓缩乙腈,加入DCM(31.5L,7V)搅拌溶清,配 制碳酸氢钠(1.35kg,2eq)和亚硫酸钠(1kg,1eq)的混合溶液(22.5L,5V),控温25℃滴加到反 应液中,搅拌分液,有机相用碳酸氢钠(1.35kg,2eq)的水溶液(22.5L)洗涤,分液,浓缩;然后 用甲苯(25L)打浆1h,过滤,滤饼用甲苯(2.5L)淋洗后,得式(Ⅶ)化合物,类白色固体(5.35kg, 收率:97.2%)。Add the compound of formula (Ⅷ) (4.5kg, 1eq) and acetonitrile (22.5L, 5V) into the 30L reactor. Under the protection of nitrogen, the temperature is controlled at 25°C, NIS (2.34kg, 1.3eq) is added in batches, and the addition is completed. Continue to add trifluoroacetic acid (183.9 g, 0.2 eq) dropwise under temperature control. After the drop is complete, react at 25° C. for 4 h. TLC shows that the raw material has been completely reacted. Concentrate acetonitrile, add DCM (31.5L, 7V) and stir to dissolve, prepare a mixed solution (22.5L, 5V) of sodium bicarbonate (1.35kg, 2eq) and sodium sulfite (1kg, 1eq), add dropwise to the reaction at 25°C liquid, stirred and separated, the organic phase was washed with an aqueous solution (22.5L) of sodium bicarbonate (1.35kg, 2eq), separated and concentrated; then it was beaten with toluene (25L) for 1h, filtered, and the filter cake was washed with toluene (2.5L ), the compound of formula (VII) was obtained as an off-white solid (5.35 kg, yield: 97.2%).

2)式(Ⅵ)化合物制备:2) preparation of formula (Ⅵ) compound:

Figure BDA0003231447290000102
Figure BDA0003231447290000102

式(Ⅶ)化合物(600g,1eq)溶于THF(9L,15V)中,置于20L高压釜中,加入三乙胺(176.4 g,2eq)、钯碳(湿品40.5g(含水55.6%),3%按干基质量计),氮气置换两次后,氘气加压至常压, 釜内升温至60℃后,氘气加压至1.0MPa左右,期间补氘气保持压力至1.0MPa,约0.5h压力基本 不变,继续控温搅拌1h后,降温至20℃,氮气置换一次,TLC显示反应完毕,加入500mL水, 搅拌5min,放出反应液,用400mL THF洗涤,过滤,滤饼用THF和水淋洗,滤液浓缩,加入DCM (4.2L)和水(3L),分液,有机层用水洗涤(3L),过滤,有机相浓缩,甲苯(3.6L)打浆,过滤, 得式(Ⅵ)化合物,类白色固体(451g,收率:92%),产物氘代率大于99%。The compound of formula (VII) (600g, 1eq) was dissolved in THF (9L, 15V), placed in a 20L autoclave, triethylamine (176.4 g, 2eq), palladium carbon (wet product 40.5g (water content 55.6%) , 3% by mass on a dry basis), after nitrogen replacement twice, deuterium is pressurized to normal pressure, after the temperature in the kettle is raised to 60°C, deuterium is pressurized to about 1.0MPa, and deuterium is added during the period to maintain the pressure to 1.0MPa , the pressure remained basically unchanged for about 0.5h. After continuing to control the temperature and stir for 1h, lower the temperature to 20°C and replace with nitrogen once. TLC showed that the reaction was complete. Add 500mL of water, stir for 5min, release the reaction solution, wash with 400mL THF, filter, Rinse with THF and water, concentrate the filtrate, add DCM (4.2L) and water (3L), separate the layers, wash the organic layer with water (3L), filter, concentrate the organic phase, beat toluene (3.6L), and filter to obtain the formula (Ⅵ) compound, off-white solid (451 g, yield: 92%), the deuteration rate of the product is greater than 99%.

3)式(Ⅴ)化合物制备:3) preparation of formula (Ⅴ) compound:

Figure BDA0003231447290000103
Figure BDA0003231447290000103

式(Ⅵ)化合物(451g,1eq)加至DCM(4.51L,10V)中,氮气保护下,降内温至-30℃,滴加三氯化硼的二氯甲烷溶液(3.56L,4.4eq,1N),此过程控温-25℃以下,滴毕保温搅拌0.5h后, TLC显示反应完全。控温-30℃下,滴加甲醇淬灭反应,滴毕,升内温至15℃,保温搅拌2h,滴加 正庚烷,加毕保温搅拌1h后,在氮气保护下过滤,滤饼用二氯甲烷和正庚烷的混合溶剂淋洗,将滤 饼悬浮于水(2.7L)中,缓慢滴加10wt%碳酸钠水溶液调pH值至8~9,混合物搅拌1h后过滤,滤 饼用水淋洗,收集湿滤饼,加入乙腈(1.8L),升温至回流,回流打浆1~2h,冷却至5℃,搅拌1~2 h后过滤,得式(Ⅴ)化合物,红色粉末状固体(128.7g,收率:55.0%)。The compound of formula (Ⅵ) (451g, 1eq) was added to DCM (4.51L, 10V), under the protection of nitrogen, the internal temperature was lowered to -30°C, and a dichloromethane solution of boron trichloride (3.56L, 4.4eq , 1N), during this process, the temperature was controlled below -25°C, and after dropping and stirring for 0.5h, TLC showed that the reaction was complete. At -30°C, add methanol dropwise to quench the reaction. After dropping, raise the inner temperature to 15°C and keep stirring for 2 hours. Then add n-heptane dropwise. After adding, keep stirring for 1 hour and filter under nitrogen protection. Rinse with a mixed solvent of dichloromethane and n-heptane, suspend the filter cake in water (2.7L), slowly add 10wt% sodium carbonate aqueous solution dropwise to adjust the pH to 8-9, stir the mixture for 1 hour and filter, then rinse the filter cake with water Wash, collect the wet filter cake, add acetonitrile (1.8 L), heat up to reflux, reflux beating for 1 to 2 hours, cool to 5°C, stir for 1 to 2 hours, and filter to obtain the compound of formula (Ⅴ), a red powdery solid (128.7 g, yield: 55.0%).

4)式(Ⅳ)化合物制备:4) Preparation of the compound of formula (Ⅳ):

Figure BDA0003231447290000111
Figure BDA0003231447290000111

将式(Ⅴ)化合物(0.914kg,1eq)加至四氢呋喃(8.1kg,10V)中,搅拌加热,固体基本不溶, 反应液内温升至55℃时,加入N,N-二甲基甲酰胺二甲基缩醛(1.304kg,3.5eq),控温50℃反应5h。 TLC显示原料反应完全后,停止加热,搅拌降温至20℃,将反应液浓缩,加入甲醇(9.14L,10V) 打浆1h,反应液浓缩至半固体状,加入乙酸乙酯和正庚烷的混合溶剂打浆,20±5℃搅拌1~2h后, 过滤,滤饼用正庚烷淋洗,得到式(Ⅳ)化合物,红色粉末状固体(1.059kg,收率:97.2%)。Add the compound of formula (Ⅴ) (0.914kg, 1eq) into tetrahydrofuran (8.1kg, 10V), stir and heat, the solid is basically insoluble, when the internal temperature of the reaction solution rises to 55°C, add N,N-dimethylformamide Dimethyl acetal (1.304kg, 3.5eq) was reacted at a temperature of 50°C for 5h. After TLC showed that the reaction of the raw materials was complete, stop heating, stir and cool down to 20°C, concentrate the reaction solution, add methanol (9.14L, 10V) for beating for 1h, concentrate the reaction solution to a semi-solid state, add a mixed solvent of ethyl acetate and n-heptane After beating, stirring at 20±5°C for 1-2 hours, filtering, and washing the filter cake with n-heptane, the compound of formula (IV) was obtained as a red powdery solid (1.059kg, yield: 97.2%).

5)式(Ⅲ)化合物制备:5) Preparation of the compound of formula (Ⅲ):

Figure BDA0003231447290000112
Figure BDA0003231447290000112

将式(Ⅳ)化合物(1.057kg)加至二氯甲烷(6.34L,6V)中,将反应液降温至15℃以下,加 入三乙胺(1.539kg,5eq)和4-二甲氨基吡啶(0.0186kg,0.05eq),然后滴加异丁酸酐(1.925kg, 4eq),滴加过程中,控制反应液温度不超过15℃,滴加结束后,控制反应温度10℃下反应1.5h。 TLC显示反应完全,向反应液中加入二氯甲烷(4.2L,4V),并加入0.1N的稀盐酸水溶液(10.57L, 10V),搅拌10min后,静置分层,收集有机相,然后向有机相中加入饱和碳酸氢钠水溶液(10.57L, 10V),搅拌30min后,静置分层,收取有机相,然后用水(10.57L,10V)洗涤,静置分层,无水硫 酸钠干燥,过滤,滤液浓缩,得到式(Ⅲ)化合物,红棕色油状物VV116-5,直接用于下一步反应。Add the compound of formula (IV) (1.057kg) into dichloromethane (6.34L, 6V), cool the reaction solution below 15°C, add triethylamine (1.539kg, 5eq) and 4-dimethylaminopyridine ( 0.0186kg, 0.05eq), and then add isobutyric anhydride (1.925kg, 4eq) dropwise. During the dropwise addition, control the temperature of the reaction solution not to exceed 15°C. After the dropwise addition, control the reaction temperature at 10°C for 1.5h. TLC shows that the reaction is complete, and dichloromethane (4.2L, 4V) is added to the reaction solution, and 0.1N dilute hydrochloric acid aqueous solution (10.57L, 10V) is added, after stirring for 10min, the layers are left to stand, the organic phase is collected, and then Add saturated aqueous sodium bicarbonate solution (10.57L, 10V) to the organic phase, stir for 30min, then let stand to separate layers, collect the organic phase, then wash with water (10.57L, 10V), stand to separate and dry over anhydrous sodium sulfate, After filtration, the filtrate was concentrated to obtain the compound of formula (Ⅲ), a reddish-brown oil VV116-5, which was directly used in the next reaction.

6)式(Ⅱ)化合物制备:6) Preparation of the compound of formula (II):

Figure BDA0003231447290000113
Figure BDA0003231447290000113

将上步得到的式(Ⅲ)化合物(1.7kg,1eq)加入到乙醇(13.6L,8V)中,加入乙酸(3.658kg, 20eq),反应液加热至50℃,55℃控温反应9h。TLC显示原料反应完全。将反应液浓缩,浓缩至无 液滴滴下后,加入乙酸乙酯(13.6L,8V)稀释,然后加入饱和碳酸氢钠溶液中和乙酸,搅拌1h后, 取水相检测pH值约7~8,静置分层,收取有机相,然后用饱和氯化钠溶液(10.2L,6V)洗涤,静 置分层,无水硫酸钠干燥,过滤,滤液浓缩,得到式(Ⅱ)化合物,红棕色油状物VV116-6。The compound of formula (III) obtained in the previous step (1.7kg, 1eq) was added to ethanol (13.6L, 8V), and acetic acid (3.658kg, 20eq) was added, and the reaction solution was heated to 50°C, and the temperature was controlled at 55°C for 9h. TLC showed the starting material was completely reacted. Concentrate the reaction solution until there is no liquid drop, add ethyl acetate (13.6L, 8V) to dilute, then add saturated sodium bicarbonate solution to neutralize the acetic acid, stir for 1 hour, take the water phase to measure the pH value of about 7-8, Stand to separate layers, collect the organic phase, then wash with saturated sodium chloride solution (10.2L, 6V), stand to separate layers, dry over anhydrous sodium sulfate, filter, and concentrate the filtrate to obtain the compound of formula (II) as a reddish-brown oil Object VV116-6.

7)式(Ⅰ)化合物制备:7) Preparation of the compound of formula (I):

Figure BDA0003231447290000121
Figure BDA0003231447290000121

将式(Ⅱ)化合物(1.256kg,1eq)加入到乙腈(8.79L,7V)中,降温至15℃以下,滴加48% 氢溴酸(0.421kg,1eq),滴加结束后,20℃搅拌1h,浓缩。反应液浓缩至小体积后,加入甲基叔 丁醚(8.79L,7V),加热至回流,回流搅拌2h,自然降温至20±5℃,搅拌12h。反应液过滤,得 到式(Ⅰ)化合物,类白色粉末状固体(1.05kg,收率:72.2%)。The compound of formula (II) (1.256kg, 1eq) was added to acetonitrile (8.79L, 7V), cooled to below 15°C, and 48% hydrobromic acid (0.421kg, 1eq) was added dropwise. Stir for 1h and concentrate. After the reaction solution was concentrated to a small volume, methyl tert-butyl ether (8.79L, 7V) was added, heated to reflux, stirred at reflux for 2h, cooled naturally to 20±5°C, and stirred for 12h. The reaction solution was filtered to obtain the compound of formula (I) as an off-white powdery solid (1.05kg, yield: 72.2%).

实施例2Example 2

本实施例提供一种式(Ⅰ)化合物的制备方法,除步骤2)外,其余同实施例1。This embodiment provides a preparation method of the compound of formula (I), which is the same as that of Embodiment 1 except step 2).

2)式(Ⅵ)化合物制备:2) preparation of formula (Ⅵ) compound:

Figure BDA0003231447290000122
Figure BDA0003231447290000122

式(Ⅶ)化合物(3.44g,1eq)溶于超干THF(20mL,购自安耐吉),加入重水(1.8mL,20eq), 50℃下浓缩至干,随后加入超干THF(20mL)、锌粉(981mg,3eq)和重水(1.8mL,20eq), 冰浴下,滴入三氯氧磷(1.15g,1.5eq)。加毕,撤去冰浴,室温下搅拌,30分钟后,TLC显示原料 反应完全。过滤,滤渣用乙酸乙酯洗涤,向滤液中加入乙酸乙酯(100mL),用饱和碳酸氢钠和饱和 食盐水洗,无水硫酸钠干燥,浓缩溶剂至干,残余物使用甲苯(25mL)打浆,过滤,得式(Ⅵ)化 合物,类白色固体(2.2g,收率:78%),产物氘代率大于98%。The compound of formula (VII) (3.44g, 1eq) was dissolved in ultra-dry THF (20mL, purchased from Anaiji), added heavy water (1.8mL, 20eq), concentrated to dryness at 50°C, and then added ultra-dry THF (20mL) , zinc powder (981mg, 3eq) and heavy water (1.8mL, 20eq), under ice-cooling, drop phosphorus oxychloride (1.15g, 1.5eq). After the addition, the ice bath was removed and stirred at room temperature. After 30 minutes, TLC showed that the reaction of the raw materials was complete. Filter, wash the filter residue with ethyl acetate, add ethyl acetate (100 mL) to the filtrate, wash with saturated sodium bicarbonate and saturated brine, dry over anhydrous sodium sulfate, concentrate the solvent to dryness, and use toluene (25 mL) to make a slurry for the residue. After filtration, the compound of formula (VI) was obtained as an off-white solid (2.2 g, yield: 78%), and the deuteration rate of the product was greater than 98%.

实施例3Example 3

本实施例提供一种式(Ⅰ)化合物的制备方法,除步骤2)外,其余同实施例1。This embodiment provides a preparation method of the compound of formula (I), which is the same as that of Embodiment 1 except step 2).

2)式(Ⅵ)化合物制备:2) preparation of formula (Ⅵ) compound:

Figure BDA0003231447290000123
Figure BDA0003231447290000123

将式(Ⅶ)化合物(2g,2.90mmol)溶于超干四氢呋喃(30mL)中,然后加入重水(3mL)浓 缩干,上述操作重复1次,将处理过的式(Ⅶ)化合物溶于四氢呋喃(30mL)中,然后加入锌粉(943 mg,14.50mmol),氮气保护下,0-5℃缓慢滴加6N的氘代盐酸的重水溶液(2.0mL,12.00mmol), 保温搅拌30分钟后,TLC显示原料消失,将反应液过滤,然后加入水和乙酸乙酯,静置分层,水相用 乙酸乙酯萃取1次,合并有机相,依次用饱和碳酸氢钠和饱和食盐水洗涤,无水硫酸钠干燥,过滤, 浓缩,甲基叔丁基醚打浆,得式(VI)化合物,类白色固体(1.1g,收率:68%),产物氘代率大于98%。Dissolve the compound of formula (VII) (2g, 2.90mmol) in ultra-dry tetrahydrofuran (30mL), then add heavy water (3mL) and concentrate to dryness. The above operation is repeated once, and the treated compound of formula (VII) is dissolved in tetrahydrofuran ( 30mL), then add zinc powder (943 mg, 14.50mmol), under the protection of nitrogen, slowly add 6N heavy aqueous solution of deuterated hydrochloric acid (2.0mL, 12.00mmol) dropwise at 0-5°C, keep stirring for 30 minutes, TLC If the raw material disappeared, the reaction solution was filtered, then water and ethyl acetate were added, and the layers were separated. The aqueous phase was extracted once with ethyl acetate, and the organic phases were combined, washed successively with saturated sodium bicarbonate and saturated brine, and anhydrous Dry over sodium sulfate, filter, concentrate, and beat with methyl tert-butyl ether to obtain the compound of formula (VI) as an off-white solid (1.1 g, yield: 68%), and the deuteration rate of the product is greater than 98%.

产业上的可利用性Industrial availability

本发明的提供的抗病毒核苷类似物VV116的制备方法,可在工业上应用。The preparation method of the antiviral nucleoside analog VV116 provided by the present invention can be applied in industry.

以上已经描述了本公开的各实施例,上述说明是示例性的,并非穷尽性的,并且也不限于所披露 的各实施例。在不偏离所说明的各实施例的范围和精神的情况下,对于本技术领域的普通技术人员来 说许多修改和变更都是显而易见的。本文中所用术语的选择,旨在最好地解释各实施例的原理、实际 应用或对市场中的技术的改进,或者使本技术领域的其它普通技术人员能理解本文披露的各实施例。Having described various embodiments of the present disclosure above, the foregoing description is exemplary, not exhaustive, and is not limited to the disclosed embodiments. Many modifications and alterations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments. The choice of terminology used herein is intended to best explain the principle of each embodiment, practical application or improvement to the technology in the market, or to enable other persons of ordinary skill in the art to understand each embodiment disclosed herein.

Claims (10)

1.一种式(Ⅰ)化合物的制备方法,其包括以下步骤:1. A preparation method of a compound of formula (I), comprising the following steps: 1)式(Ⅷ)化合物与试剂A在酸作用下反应,得到式(Ⅶ)化合物:1) The compound of formula (Ⅷ) reacts with reagent A under the action of acid to obtain the compound of formula (Ⅶ):
Figure FDA0003231447280000011
Figure FDA0003231447280000011
其中,X为卤素;Wherein, X is a halogen; 2)式(Ⅶ)化合物与试剂B在金属试剂M作用下反应,得到式(Ⅵ)化合物:2) The compound of formula (VII) reacts with reagent B under the action of metal reagent M to obtain the compound of formula (VI):
Figure FDA0003231447280000012
Figure FDA0003231447280000012
3)式(Ⅵ)化合物与试剂C反应,得到式(Ⅴ)化合物:3) The compound of formula (Ⅵ) reacts with reagent C to obtain the compound of formula (Ⅴ):
Figure FDA0003231447280000013
Figure FDA0003231447280000013
4)式(Ⅴ)化合物与试剂D反应,得到式(Ⅳ)化合物:4) The compound of formula (Ⅴ) reacts with reagent D to obtain the compound of formula (Ⅳ):
Figure FDA0003231447280000014
Figure FDA0003231447280000014
5)式(Ⅳ)化合物与试剂E在有机碱作用下反应,得到式(Ⅲ)化合物:5) The compound of formula (Ⅳ) reacts with reagent E under the action of an organic base to obtain the compound of formula (Ⅲ):
Figure FDA0003231447280000015
Figure FDA0003231447280000015
6)式(Ⅲ)化合物与试剂F反应,得到式(Ⅱ)化合物:6) The compound of formula (Ⅲ) reacts with reagent F to obtain the compound of formula (Ⅱ):
Figure FDA0003231447280000021
Figure FDA0003231447280000021
7)式(Ⅱ)化合物与试剂G反应,得到式(Ⅰ)化合物:7) The compound of formula (II) reacts with reagent G to obtain the compound of formula (I):
Figure FDA0003231447280000022
Figure FDA0003231447280000022
2.根据权利要求1所述的式(Ⅰ)化合物的制备方法,其特征在于,步骤1)中,2. The preparation method of the compound of formula (I) according to claim 1, characterized in that, in step 1), X为I、Br或Cl,所述试剂A为N-碘代丁二酰亚胺、I2、Br2、N-溴代丁二酰亚胺、二溴海因或N-氯代丁二酰亚胺中的一种;优选地,X为I或Br,所述试剂A为N-碘代丁二酰亚胺、I2、Br2、N-溴代丁二酰亚胺或二溴海因中的一种;更优选地,X为I,所述试剂A为N-碘代丁二酰亚胺;X is I, Br or Cl, and the reagent A is N-iodosuccinimide, I 2 , Br 2 , N-bromosuccinimide, dibromohydantoin or N-chlorobutanedi One of imides; preferably, X is I or Br, and the reagent A is N-iodosuccinimide, I 2 , Br 2 , N-bromosuccinimide or dibromo One of hydantoin; more preferably, X is I, and the reagent A is N-iodosuccinimide; 所述酸为有机酸,优选为三氟乙酸、三氯乙酸或醋酸中的一种,更优选为三氟乙酸;The acid is an organic acid, preferably one of trifluoroacetic acid, trichloroacetic acid or acetic acid, more preferably trifluoroacetic acid; 反应溶剂为N,N-二甲基甲酰胺、四氢呋喃或乙腈中的一种,优选为乙腈;The reaction solvent is one of N,N-dimethylformamide, tetrahydrofuran or acetonitrile, preferably acetonitrile; 反应温度为0~50℃,优选为20~30℃,更优选为25℃;The reaction temperature is 0-50°C, preferably 20-30°C, more preferably 25°C; 其中,所述式(Ⅷ)化合物、所述试剂A和所述酸的摩尔比为1:(1~1.5):(0.1~0.5),优选为1:1.3:0.2。Wherein, the molar ratio of the compound of formula (VIII), the reagent A and the acid is 1:(1-1.5):(0.1-0.5), preferably 1:1.3:0.2. 3.根据权利要求1或2所述的式(Ⅰ)化合物的制备方法,其特征在于,步骤2)中,所述试剂B为氘气、氘代酸性试剂或重水中的一种。3. The preparation method of the compound of formula (I) according to claim 1 or 2, characterized in that, in step 2), the reagent B is one of deuterium gas, deuterated acidic reagent or heavy water. 4.根据权利要求3所述的式(Ⅰ)化合物的制备方法,其特征在于,步骤2)中,所述式(Ⅶ)化合物与所述氘气在所述金属试剂M和有机碱作用下反应;4. the preparation method of formula (I) compound according to claim 3, is characterized in that, in step 2), described formula (VII) compound and described deuterium gas are under the action of described metal reagent M and organic base reaction; 所述金属试剂M为钯催化剂,优选为钯碳;所述有机碱为三乙胺、N,N-二异丙基乙基胺、三甲胺、氨气、氨水、DBU或吡啶中的一种,优选为三乙胺;反应溶剂为四氢呋喃、甲醇、乙醇、异丙醇或乙酸乙酯中的一种,优选为四氢呋喃;反应压力为0.1~2MPa,优选为1.0MPa;反应温度为25~65℃,优选为55~65℃;The metal reagent M is a palladium catalyst, preferably palladium carbon; the organic base is one of triethylamine, N,N-diisopropylethylamine, trimethylamine, ammonia gas, ammonia water, DBU or pyridine , preferably triethylamine; the reaction solvent is one of tetrahydrofuran, methanol, ethanol, isopropanol or ethyl acetate, preferably tetrahydrofuran; the reaction pressure is 0.1-2MPa, preferably 1.0MPa; the reaction temperature is 25-65 °C, preferably 55-65 °C; 其中,所述式(Ⅶ)化合物与所述钯碳干基的质量比为1:(0.01~0.2),所述式(Ⅶ)化合物与所述有机碱的摩尔比为1:(1~3)。Wherein, the mass ratio of the compound of the formula (VII) to the dry base of the palladium carbon is 1:(0.01~0.2), and the molar ratio of the compound of the formula (VII) to the organic base is 1:(1~3 ). 5.根据权利要求3所述的式(Ⅰ)化合物的制备方法,其特征在于,步骤2)中,所述式(Ⅶ)化合物与所述氘代酸性试剂在所述金属试剂M作用下反应;5. the preparation method of formula (I) compound according to claim 3 is characterized in that, in step 2), described formula (VII) compound reacts with described deuterated acidic reagent under the action of described metal reagent M ; 所述氘代酸性试剂为氘代盐酸、氘代硫酸、氘代醋酸、氘代三氟乙酸或氘代氯化铵中的一种;所述金属试剂M为锌和/或铁;反应溶剂为超干四氢呋喃;反应温度为0~50℃,优选为20~30℃;The deuterated acid reagent is one of deuterated hydrochloric acid, deuterated sulfuric acid, deuterated acetic acid, deuterated trifluoroacetic acid or deuterated ammonium chloride; the metal reagent M is zinc and/or iron; the reaction solvent is Ultra-dry tetrahydrofuran; the reaction temperature is 0-50°C, preferably 20-30°C; 其中,所述式(Ⅶ)化合物、所述氘代酸性试剂与所述金属试剂M的摩尔比为1:(4.0~4.5):(4.0~6.0)。Wherein, the molar ratio of the compound of formula (VII), the deuterated acidic reagent and the metal reagent M is 1:(4.0-4.5):(4.0-6.0). 6.根据权利要求3所述的式(Ⅰ)化合物的制备方法,其特征在于,步骤2)中,所述式(Ⅶ)化合物与所述重水在所述金属试剂M和试剂B'作用下反应;6. The preparation method of the compound of formula (I) according to claim 3, characterized in that, in step 2), the compound of formula (VII) and the heavy water are under the action of the metal reagent M and reagent B' reaction; 所述金属试剂M为锌和/或铁;所述试剂B'为三氯氧磷、三氯化磷、三溴化磷、三氯化硼或三氯化铝中的一种;反应溶剂为超干四氢呋喃;反应温度为0~50℃,优选为室温;The metal reagent M is zinc and/or iron; the reagent B' is one of phosphorus oxychloride, phosphorus trichloride, phosphorus tribromide, boron trichloride or aluminum trichloride; the reaction solvent is Ultra-dry tetrahydrofuran; the reaction temperature is 0-50°C, preferably room temperature; 其中,所述式(Ⅶ)化合物、所述重水、所述金属试剂M与试剂B'的摩尔比为1:(15~25):(2~4):(1~2)。Wherein, the molar ratio of the compound of formula (VII), the heavy water, the metal reagent M and the reagent B' is 1:(15-25):(2-4):(1-2). 7.根据权利要求1-6任一项所述的式(Ⅰ)化合物的制备方法,其特征在于,步骤3)中,所述试剂C为三氯化硼或三溴化硼,反应溶剂为二氯甲烷,反应温度为-35~-25℃;7. according to the preparation method of the compound of formula (I) described in any one of claim 1-6, it is characterized in that, in step 3), described reagent C is boron trichloride or boron tribromide, and reaction solvent is Dichloromethane, the reaction temperature is -35~-25°C; 其中,所述式(Ⅵ)化合物与所述试剂C的摩尔比为1:(3~6)。Wherein, the molar ratio of the compound of formula (VI) to the reagent C is 1:(3-6). 8.根据权利要求1-7任一项所述的式(Ⅰ)化合物的制备方法,其特征在于,步骤4)中,所述试剂D为N,N-二甲基甲酰胺二甲基缩醛或N,N-二甲基甲酰胺二乙基缩醛,优选N,N-二甲基甲酰胺二甲基缩醛;反应溶剂为四氢呋喃;反应温度为20~55℃,优选为45~55℃;8. The preparation method of the compound of formula (I) according to any one of claims 1-7, characterized in that, in step 4), the reagent D is N,N-dimethylformamide dimethyl acetal Aldehyde or N,N-dimethylformamide diethyl acetal, preferably N,N-dimethylformamide dimethyl acetal; the reaction solvent is tetrahydrofuran; the reaction temperature is 20~55℃, preferably 45~ 55°C; 其中,所述式(Ⅴ)化合物与所述试剂D的摩尔比为1:(2~4)。Wherein, the molar ratio of the compound of formula (V) to the reagent D is 1:(2-4). 9.根据权利要求1-8任一项所述的式(Ⅰ)化合物的制备方法,其特征在于,步骤5)中,所述试剂E为异丁酰氯、异丁酸酐或异丁酸中的一种;9. according to the preparation method of the compound of formula (I) described in any one of claim 1-8, it is characterized in that, in step 5), described reagent E is in isobutyryl chloride, isobutyric anhydride or isobutyric acid A sort of; 当所述试剂E为异丁酰氯或异丁酸酐时,所述式(Ⅳ)化合物与所述试剂E在有机碱和催化剂作用下反应,所述有机碱为三乙胺和/或N,N-二异丙基乙基胺,优选三乙胺;所述催化剂为4-二甲基氨基吡啶;反应溶剂为二氯甲烷;反应温度为5~30℃,优选为5~15℃;When the reagent E is isobutyryl chloride or isobutyric anhydride, the compound of formula (IV) reacts with the reagent E under the action of an organic base and a catalyst, and the organic base is triethylamine and/or N,N - diisopropylethylamine, preferably triethylamine; the catalyst is 4-dimethylaminopyridine; the reaction solvent is dichloromethane; the reaction temperature is 5-30°C, preferably 5-15°C; 其中,所述式(Ⅳ)化合物、所述试剂E、所述有机碱和所述催化剂的摩尔比为1:(3~5):(4~6):(0.01~0.1);Wherein, the molar ratio of the compound of formula (IV), the reagent E, the organic base and the catalyst is 1:(3-5):(4-6):(0.01-0.1); 当试剂E为异丁酸时,所述式(Ⅳ)化合物与所述试剂E在有机碱和缩合剂作用下反应,所述有机碱为三乙胺和/或N,N-二异丙基乙基胺;所述缩合剂为二环己基碳二亚胺、1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐或1-羟基苯并三唑中的一种;反应溶剂为二氯甲烷;反应温度为5~30℃,优选为5~15℃。When the reagent E is isobutyric acid, the compound of formula (IV) reacts with the reagent E under the action of an organic base and a condensing agent, and the organic base is triethylamine and/or N,N-diisopropyl Ethylamine; the condensing agent is dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride or 1-hydroxybenzotriazole One; the reaction solvent is dichloromethane; the reaction temperature is 5-30°C, preferably 5-15°C. 10.根据权利要求1-9任一项所述的式(Ⅰ)化合物的制备方法,其特征在于,步骤6)中,所述试剂F为乙酸、三氟乙酸、盐酸或水合肼中的一种,优选为乙酸;反应溶剂为乙醇、异丙醇、四氢呋喃或乙腈中的一种,优选为乙醇;反应温度为0~55℃,优选为45~55℃;其中,所述(Ⅲ)化合物与所述试剂F的摩尔比为1:(15~25);10. The preparation method of the compound of formula (I) according to any one of claims 1-9, characterized in that, in step 6), the reagent F is one of acetic acid, trifluoroacetic acid, hydrochloric acid or hydrazine hydrate species, preferably acetic acid; the reaction solvent is one of ethanol, isopropanol, tetrahydrofuran or acetonitrile, preferably ethanol; the reaction temperature is 0 to 55°C, preferably 45 to 55°C; wherein, the (Ⅲ) compound The molar ratio with the reagent F is 1:(15~25); 步骤7)中,所述试剂G为氢溴酸,反应温度为15~25℃;其中,所述式(Ⅱ)化合物与所述试剂G的摩尔比为1:(1~1.2)。In step 7), the reagent G is hydrobromic acid, and the reaction temperature is 15-25°C; wherein, the molar ratio of the compound of formula (II) to the reagent G is 1:(1-1.2).
CN202110988001.1A 2021-08-26 2021-08-26 Preparation method of antiviral nucleoside analogue Pending CN115716833A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110988001.1A CN115716833A (en) 2021-08-26 2021-08-26 Preparation method of antiviral nucleoside analogue

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110988001.1A CN115716833A (en) 2021-08-26 2021-08-26 Preparation method of antiviral nucleoside analogue

Publications (1)

Publication Number Publication Date
CN115716833A true CN115716833A (en) 2023-02-28

Family

ID=85253546

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110988001.1A Pending CN115716833A (en) 2021-08-26 2021-08-26 Preparation method of antiviral nucleoside analogue

Country Status (1)

Country Link
CN (1) CN115716833A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023143630A1 (en) * 2022-01-26 2023-08-03 苏州旺山旺水生物医药有限公司 Preparation method for nucleoside analogue vv116
US11963967B2 (en) 2020-10-16 2024-04-23 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
US12030904B2 (en) 2020-08-24 2024-07-09 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
WO2024230834A1 (en) * 2023-05-11 2024-11-14 浙江华海药业股份有限公司 Method for continuously preparing deuremidevir hydrobromide

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12030904B2 (en) 2020-08-24 2024-07-09 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
US11963967B2 (en) 2020-10-16 2024-04-23 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
US12208110B2 (en) 2020-10-16 2025-01-28 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
WO2023143630A1 (en) * 2022-01-26 2023-08-03 苏州旺山旺水生物医药有限公司 Preparation method for nucleoside analogue vv116
WO2024230834A1 (en) * 2023-05-11 2024-11-14 浙江华海药业股份有限公司 Method for continuously preparing deuremidevir hydrobromide

Similar Documents

Publication Publication Date Title
CN115716833A (en) Preparation method of antiviral nucleoside analogue
CN111943932B (en) 3-pyridine sulfonyl-1-N-hetero pyrrole derivative capable of treating peptic ulcer and preparation method and application thereof
CN101163698B (en) Method for the production of 5-(4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide
CN106083691B (en) A kind of preparation method of arbidol HCl monohydrate
CN114516875B (en) A kind of preparation method of nucleoside analogue VV116
CN106632335A (en) Preparation method of valaciclovir hydrochloride
CN110218233B (en) P (P) 1 ,P 4 Preparation method of di (uridine 5' -tetraphosphate)
CN104557701A (en) Preparation method of isoquinoline derivative
CN103896889B (en) Lapatinib intermediate and its preparation method and application
CN106008499A (en) Method for preparing CDK46 kinase inhibitor Palbociclib
CN107556355B (en) Nucleoside diphosphite amide and preparation method thereof
WO2020029647A1 (en) Method for synthesizing nucleoside compound and intermediate thereof
CN104447548A (en) Process for synthesizing substituted isoquinolines
CN116655576B (en) Preparation method of flavonoid compound GL-V9
CN106083856A (en) A kind of purines alanine derivatives that can be used for oncotherapy and its preparation method and application
Rawson et al. The Synthesis of 5′-Homo-2′-deoxycytidine
CN111875661B (en) Method for separating and purifying abiraterone and dimer thereof
CN118754877B (en) A tracer precursor compound targeting FAP, preparation and application thereof
CN115322120B (en) Small molecule compound and application thereof in preparation of medicine for treating DHODH-mediated diseases
WO1983002944A1 (en) NOVEL s-TRIAZOLEAD1,5-aBDPYRIMIDINE DERIVATIVES
JP2001507711A (en) Preparation of tetrazolylbenzopyran
CN112979721B (en) Preparation method of high-purity antineoplastic medicine troflucytidine
CN103601779A (en) Synthetic method of 7-denitrified-2'-deoxidized-7-halogen substituted guanosine
CN116102440A (en) Preparation method of 1- (3, 4-diaminophenyl) ethanone
CN104098523B (en) 1-isobutyryl-3-phenyl-Isosorbide-5-Nitrae-dihydro-1,2,4,5-tetrazine and preparation and application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination